Other studies have shown [80,81] that a high ratio of RANKL to its endogenous antagonist osteoprotegerin (RANKL:OPG) characterized MM patients with shorter survival, where high levels of soluble RANKL correlated with the degree of bone damage [80,81]. This evidence concerns the gene TNFRSF11B and Miyoshi myopathy.